Dr. Sharma is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2330 Shawnee Mission Pkwy
Ste 210
Westwood, KS 66205Phone+1 913-588-6029Fax+1 913-588-9822
Education & Training
- University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2005
- University of Kansas School of MedicineChief Residency, Internal Medicine, 2001 - 2002
- University of Kansas School of MedicineResidency, Internal Medicine, 1999 - 2001
- Baroda Medical CollegeClass of 1997
Certifications & Licensure
- KS State Medical License 2001 - 2025
- MO State Medical License 2021 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy Start of enrollment: 2009 Mar 01
- Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. Start of enrollment: 2009 May 01
- Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression Start of enrollment: 2009 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 80 citationsPathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus DocetaxelPriyanka Sharma, Sara López-Tarruella, José A. García-Sáenz, Qamar J. Khan, Henry L. Gomez
Clinical Cancer Research. 2018-12-01 - 47 citationsRandomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer...Priyanka Sharma, Bruce F. Kimler, Anne O'Dea, Lauren Nye, Yen Y. Wang
Clinical Cancer Research. 2021-02-15 - 22 citationsClinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.Priyanka Sharma, Shane R Stecklein, Rachel Yoder, Joshua M Staley, Kelsey Schwensen
JAMA Oncology. 2024-02-01
Journal Articles
- Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus DocetaxelAmanda Amin, Jamie Wagner, Qamar J Khan, Roy A Jensen, Joshua M Mammen, Priyanka Sharma, Jennifer R Klemp, Clinical Cancer Research
Press Mentions
- Summing It Up: Neoadjuvant Therapy in Triple-Negative DiseaseApril 6th, 2023
- Focus on Optimizing Use of CDK4/6 Inhibitors in Metastatic HR+ Breast CancerMarch 8th, 2023
- Addition of Veliparib to Cisplatin in Advanced Triple-Negative Breast Cancer with BRCA-like and Non–BRCA-like PhenotypeJanuary 23rd, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: